Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Novo Nordisk A/S ADR (NY: NVO )

124.17 -3.34 (-2.62%)
Streaming Delayed Price Updated: 11:03 AM EDT, Sep 23, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 3,265,305
Open 124.00
Bid (Size) 124.15 (1)
Ask (Size) 124.21 (1)
Prev. Close 127.51
Today's Range 122.94 - 124.70
52wk Range 86.96 - 148.15
Shares Outstanding N/A
Dividend Yield 1.42%
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Novo Nordisk's Options: A Look at What the Big Money is Thinking
Via Benzinga
Bernie Sanders Questions Why Your Monthly Ozempic Prescription Costs More Than A Luxury Handbag When It Can Be Sold For Less Than $100
Via Benzinga

Performance

YTD
+21.60%
+21.60%
1 Month
-9.35%
-9.35%
3 Month
-12.73%
-12.73%
6 Month
-3.78%
-3.78%
1 Year
+36.26%
+36.26%

More News

Read More
Novo Nordisk, Chewy And FedEx Are Among Top 10 Large Cap Losers Last Week (Sept 15-Sept 21): Are The Others In Your Portfolio?
Via Benzinga
3 Stocks That Could Rise on European Bank Interest Rate Cuts
Via MarketBeat
Topics Economy
Exposures Interest Rates
Spotlight on Novo Nordisk: Analyzing the Surge in Options Activity
Via Benzinga
If You Invested $1000 In This Stock 10 Years Ago, You Would Have $5,700 Today
Via Benzinga
Netflix, Eli Lilly Lead 5 Fast Growers Near Buy Points
Via Investor's Business Daily
Why Novo Nordisk Stock Fell While Eli Lilly and Viking Therapeutics Bumped Higher Today
Via The Motley Fool
US Federal Trade Commission Sues CVS Health, Cigna, UnitedHealth's Pharmacy Benefit Managers For Inflating Insulin Prices
Via Benzinga
Topics Lawsuit
Exposures Financial Legal
Novo Nordisk's Monlunabant Data Drags Stocks Of Smaller Players
Via Benzinga
Corbus Pharma (CRBP) Stock Drops 60% After Novo Nordisk's Cannabinoid-Based Weight Loss Drug Trial Disappoints
Via Benzinga
Novo Nordisk Stock Declines After Headline Results From Mid-Stage Study Of Monlunabant In Obese Patients
Via Benzinga
Novo Dives — And Corbus Crashes — After New Weight-Loss Drug Causes Neuropsychiatric Effects
Via Investor's Business Daily
European Drug Agency Supports Novo Nordisk's Blockbuster Weight-Loss Drug Wegovy For Obesity-Related Heart Failure
Via Benzinga
Hims & Hers To Offer Access To Compounded Diabetes And Weight Loss Drugs For Just $99/Month To Certain Professional Personnel
Via Benzinga
Viking Therapeutics Is Having a Year to Remember: Time to Buy?
Via MarketBeat
Novo Nordisk Just Took a $530 Million Step Onto Moderna's Turf. Here's What It Means for Both Stocks
Via The Motley Fool
Novo Nordisk Inks $600M Genetic Medicines Pact With Canadian Firm To Target Cardiometabolic Indications
Via Benzinga
1 Telemedicine Stock I Wouldn't Touch With a 10-Foot Pole (Hint: It's Not Teladoc)
Via The Motley Fool
2 Unstoppable Healthcare Stocks to Buy Right Now for Less Than $200
Via The Motley Fool
Time To Invest And Or Trade In Bio-Tech Stocks?
Via Talk Markets
Topics ETFs
Stock Market Rally Revives; Apple iPhone 16, Nvidia, Oracle, Adobe In Focus: Weekly Review
Via Investor's Business Daily
3 No-Brainer Biotech Stocks to Buy With $200 Right Now
Via The Motley Fool
Why Roche Holdings Stock Withered on Wednesday
Via The Motley Fool
Why Viking Therapeutics Stock Rocked the Market Today
Via The Motley Fool
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.